CD8A and hematologic disorder: In these assays, we used PBMCs (peripheral blood mononuclear cells) from four patients with a hematological malignancy who developed HA1-specific CD8+ T cell responses after alloSCT, and stimulated them for one week with TLR-matured HA1 peptide-loaded HSPC-DCs or MoDCs, generated from unrelated third-party HLA-A2+HA1− donors.